HealthcareLtd Management

Management Kriterienprüfungen 4/4

HealthcareLtd's CEO ist Zhang Gen Ni , ernannt in Oct 2012, hat eine Amtszeit von 11.67 Jahren. besitzt direkt 33.81% der Aktien des Unternehmens, im Wert von CN¥1.48B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 11.7 Jahre bzw. 9.9 Jahre.

Wichtige Informationen

Zhang Gen Ni

Geschäftsführender

CN¥804.8k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	11.9yrs
Eigentum des Geschäftsführers	34.0%
Durchschnittliche Amtszeit des Managements	11.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	10.1yrs

Jüngste Management Updates

Recent updates

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Sep 26

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Sep 06

Geschäftsführer

Zhang Gen Ni (49 yo)

11.9yrs

Amtszeit

CN¥804,800

Vergütung

Mr. Zhang Gen Ni is Chairman of the Board & President of Healthcare Co., Ltd. since October 29, 2012. He was Chairman of the Board, General Manager and Director of Development Center of Healthcare Co., Ltd...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zhang Gen Ni	Chairman of the Board & President	11.9yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	11.9yrs	CN¥441.40k	0.0053% CN¥ 197.4k
Hong Jian Zhang	VP & Director	11.9yrs	CN¥710.30k	0.0053% CN¥ 197.4k
Hailong Zhang	Accounting Supervisor	no data	keine Daten	keine Daten

11.9yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 603313 ist erfahren und erfahren (durchschnittliche Amtszeit: 11.6 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zhang Gen Ni	Chairman of the Board & President	11.9yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	11.9yrs	CN¥441.40k	0.0053% CN¥ 197.4k
Hong Jian Zhang	VP & Director	11.9yrs	CN¥710.30k	0.0053% CN¥ 197.4k
Jian Long Ji	Director	8.3yrs	CN¥474.10k	0.0053% CN¥ 197.4k
Tao Lin	Employee Supervisor	11.9yrs	keine Daten	keine Daten
Hua Wei	Member of Supervisory Board	11.9yrs	keine Daten	keine Daten
Chang Ling Zhu	Independent Director	5.4yrs	CN¥80.00k	keine Daten
Baiming Xu	Independent Director	5.4yrs	CN¥80.00k	keine Daten
Zaifa Cai	Independent Director	5.4yrs	CN¥80.00k	keine Daten
Jian Sun	Chairman of the Supervisory Board	7.8yrs	keine Daten	keine Daten

10.1yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: 603313Die Vorstandsmitglieder sind sehr erfahren ( 10 ).

HealthcareLtd Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 18%

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Price target decreased by 60% to CN¥5.30

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Second quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.19 in 2Q 2023)

Now 22% overvalued

Healthcare Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Healthcare Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

New major risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.03 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2022)

Now 20% undervalued

Price target decreased by 10% to CN¥12.68

First quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.59 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 loss in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥15.00

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.59 loss per share (vs CN¥0.42 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥29.93

Second quarter 2021 earnings released: CN¥0.12 loss per share (vs CN¥0.17 profit in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target decreased to CN¥28.03

Price target increased to CN¥52.73

Full year 2020 earnings released: EPS CN¥1.11 (vs CN¥1.18 in FY 2019)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥43.05

New 90-day high: CN¥39.17

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: CN¥36.87

Price target raised to CN¥46.61

Analysts update estimates

Healthcare Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

Third quarter earnings released

Price target raised to CN¥36.16

Earnings released

New 90-day high - CN¥29.33

New 90-day high - CN¥26.83

Healthcare Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter